SCHEMBL24430075

SCHEMBL24430075

Cc1ccc(N2C(=O)C=C(Nc3cc(F)c(O)c(F)c3)C2=O)cc1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 7/20 0.45
▸ MEN1 O00255 6/20 0.45
▸ NPSR1 Q6W5P4 4/20 0.36
▸ ALDH1A1 P00352 5/20 0.36
▸ TSHR P16473 3/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ CASP1 P29466 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ MAPT P10636 5/20 0.35
▸ HSP90AA1 P07900 1/20 0.35
▸ G6PD P11413 1/20 0.35
▸ PKM P14618 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ CCR6 P51684 1/20 0.35
▸ MCL1 Q07820 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ GAA P10253 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ LMNA P02545 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26205862 0.90 KMT2A (0.47) KMT2AMEN1NPSR1ALDH1A1TSHR
SCHEMBL24430074 0.88 MEN1 (0.50) KMT2AMEN1ALDH1A1TSHRNPC1
SCHEMBL24430113 0.86 MEN1 (0.54) KMT2AMEN1ALDH1A1MAPTHPGD
SCHEMBL24430026 0.85 KMT2A (0.52) KMT2AMEN1NPSR1ALDH1A1MAPK1
SCHEMBL24430003 0.83 MEN1 (0.43) KMT2AMEN1ALDH1A1NPC1MAPK1
SCHEMBL24430002 0.83 MEN1 (0.48) KMT2AMEN1NPSR1ALDH1A1NPC1
SCHEMBL24430114 0.82 MEN1 (0.68) KMT2AMEN1ALDH1A1TSHRNPC1
SCHEMBL24430013 0.82 MEN1 (0.49) KMT2AMEN1ALDH1A1MAPTHSP90AA1
SCHEMBL24429999 0.82 KMT2A (0.47) KMT2AMEN1ALDH1A1NPC1MAPK1
SCHEMBL24430115 0.82 MEN1 (0.44) KMT2AMEN1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339860-A1 Compounds for the Treatment Of Acute and Chronic Kidney Disease SOUTHERN RES INST (US) 2023-10-26 — — US disclosed
US-11753374-B2 Compounds for the treatment of acute and chronic kidney disease Southern Reserach Institute (US) 2023-09-12 — — US disclosed
US-11753374-B2 Compounds for the treatment of acute and chronic kidney disease Southern Reserach Institute (US) 2023-09-12 — — US disclosed
WO-2022109066-A1 COMPOUNDS FOR THE TREATMENT OF ACUTE AND CHRONIC KIDNEY DISEASE SOUTHERN RESEARCH INSTITUTE (US) 2022-05-27 — — WO disclosed
WO-2022109067-A1 COMPOUNDS FOR THE TREATMENT OF ACUTE AND CHRONIC KIDNEY DISEASE SOUTHERN RESEARCH INSTITUTE (US) 2022-05-27 — — WO disclosed
US-20220153702-A1 Compounds for the Treatment Of Acute and Chronic Kidney Disease UAB RESEARCH FOUNDATION 2022-05-19 — — US disclosed
US-20220153695-A1 Compounds for the Treatment Of Acute and Chronic Kidney Disease THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 2022-05-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220153695-A1 Compounds for the Treatment Of Acute and Chronic Kidney Disease HMOX1, GLS, HMOX2 KMT2A 2088/4885MEN1 4171/4885NPSR1 3380/4885
US-20220153702-A1 Compounds for the Treatment Of Acute and Chronic Kidney Disease HMOX1, HMOX2, GLS KMT2A 2904/4885MEN1 4651/4885NPSR1 2385/4885
US-20230339860-A1 Compounds for the Treatment Of Acute and Chronic Kidney Disease HMOX1, HMOX2, GLS KMT2A 2904/4885MEN1 4651/4885NPSR1 2385/4885
US-11753374-B2 Compounds for the treatment of acute and chronic kidney disease HMOX1, GLS, HMOX2 KMT2A 2088/4885MEN1 4171/4885NPSR1 3380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback